{
  "source": "PA-Notification-Syprine.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1135-13\nProgram Prior Authorization/Notification\nMedication Syprine® (trientine hydrochloride)*, Trientine hydrochloride\nP&T Approval Date 7/2014, 7/2015, 6/2016, 6/2017, 6/2018, 6/2019, 6/2020, 6/2021,\n6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Backgrounda:\nSyprine (trientine hydrochloride) and trientine hydrochloride are indicated for the treatment of\npatients with Wilson’s disease who are intolerant of penicillamine. Syprine and trientine\nhydrochloride cannot be considered interchangeable with penicillamine. Syprine and trientine\nhydrochloride should be used when continued treatment with penicillamine is no longer possible\nbecause of intolerable or life endangering side effects.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Syprine* or trientine hydrochloride will be approved based on both of the following\ncriteria:\na. Diagnosis of Wilson’s disease (i.e., hepatolenticular degeneration)\n-AND-\nb. History of intolerance, failure or contraindication to penicillamine\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Syprine* or trientine hydrochloride will be approved based on the following\ncriterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Syprine® (trientine hydrochloride) is typically excluded from coverage. Tried/Failed criteria may be\nin place. Please refer to plan specifics to determine exclusion status.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval",
    " Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Syprine [package insert]. Bridgewater, NJ: Bausch Health US, LLC; September 2020.\n2. Trientine hydrochloride [package insert]. Parsippany, NJ: Teva Pharmaceuticals; January\n2022.\nProgram Prior Authorization/Notification – Syprine* (trientine hydrochloride), Trientine\nhydrochloride\nChange Control\n7/2014 New program.\n9/2014 Administrative change – Tried/Failed exemption for State of New Jersey\nremoved.\n7/2015 Annual Review. References updated. Added notation that Cuprimine is now\nexcluded from coverage.\n6/2016 Annual Review. Changed initial authorization to 12 months and added\nreauthorization for 24 months. Updated background, formatting and\nreferences.\n6/2017 Annual review. Updated references.\n6/2018 Annual review. No changes.\n6/2019 Annual review. No changes.\n6/2020 Annual review. No changes.\n6/2021 Annual review with no changes to clinical criteria. Updated references.\n6/2022 Annual review. Cuprimine and Depen removed as examples from Coverage\nCriteria as they are typically excluded from coverage and generic penicillamine\nis available. Changed reauthorization to 12 months to align with\nreauthorization period for other pharmacy programs.\n6/2023 Annual review. Added generic trientine hydrochloride to program and noted\nthat Brand Syprine is typically excluded from coverage for most plans.\nUpdated references and added state mandate footnote.\n6/2024 Annual review with no changes to criteria.\n6/2025 Annual review with no changes to criteria. Updated formatting.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}